Gocatamig
Small Cell Lung Cancer
Merck Sharp & Dohme LLCPhase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 65/ 100
Competitive context
290 Active assets in the Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benmelstobart Yayi He | Phase 4 | A |
vx-970 National Cancer Institute (NCI) | Phase 2 | BBB |
Adebelimab Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | BBB |
Veliparib Central European Society for Anticancer Drug Research | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Gocatamig is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →